Search Results - "Jimenez Bárcenas, Reyes"
-
1
Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with pre‐existing primary immune thrombocytopenia (ITP) in Spain
Published in British journal of haematology (01-08-2021)“…Summary Infections are one of the well‐known precipitating factors for relapses in patients with immune thrombocytopenia (ITP). Severe acute respiratory…”
Get full text
Journal Article -
2
P1614: TAPERING SCHEME AND SUSTAINED RESPONSE IN PATIENTS WITH ITP TREATED WITH FOSTAMATINIB
Published in HemaSphere (08-08-2023)Get full text
Journal Article -
3
Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus
Published in Platelets (Edinburgh) (01-12-2024)“…Immune thrombocytopenia (ITP) is a common autoimmune hematological disorder. Despite this, diagnosis is still challenging due to clinical heterogeneity and the…”
Get full text
Journal Article -
4
Novel Therapies to Address Unmet Needs in ITP
Published in Pharmaceuticals (Basel, Switzerland) (23-06-2022)“…Primary immune thrombocytopenia (ITP) is an autoimmune disorder that causes low platelet counts and subsequent bleeding risk. Although current…”
Get full text
Journal Article -
5
COVID-19 Vaccines and Autoimmune Hematologic Disorders
Published in Vaccines (Basel) (16-06-2022)“…Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been…”
Get full text
Journal Article -
6
Recommendations on the Management of Patients with Immune Thrombocytopenia (ITP) in the Context of SARS-CoV-2 Infection and Vaccination: Consensus Guidelines from a Spanish ITP Expert Group
Published in Infectious diseases and therapy (01-02-2023)“…Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease with highly variable presentation, characteristics, and clinical course…”
Get full text
Journal Article -
7
Platelet Responses After Tapering and Discontinuation of Fostamatinib in Patients with Immune Thrombocytopenia: A Continuation of the Fostasur Study
Published in Journal of clinical medicine (01-11-2024)“…Background/objectives: Fostamatinib is a spleen tyrosine kinase (SYK) inhibitor approved for the treatment of adult patients with chronic immune…”
Get full text
Journal Article -
8
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink
Published in Blood reviews (01-09-2023)“…There are not many publications that provide a holistic view of the management of primary and secondary ITP as a whole, reflecting the similarities and…”
Get full text
Journal Article -
9
Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study
Published in British journal of haematology (01-05-2024)“…Summary Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase…”
Get full text
Journal Article -
10
Avatrombopag in immune thrombocytopenia: A real‐world study of the Spanish ITP Group (GEPTI)
Published in American journal of hematology (01-12-2024)“…Avatrombopag is the newest thrombopoietin receptor agonist (TPO‐RA) approved to treat immune thrombocytopenia (ITP). Real‐world evidence regarding…”
Get full text
Journal Article -
11
Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia
Published in Blood coagulation & fibrinolysis (01-06-2018)“…Thrombopoietin receptor agonist (TPO-RAs) have demonstrated good efficacy and tolerance in clinical trials in refractory chronic primary immune…”
Get full text
Journal Article -
12
Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia
Published in Platelets (Edinburgh) (01-01-2015)“…Abstract Eltrombopag is effective and safe in chronic immune thrombocytopenia (ITP) patients not responding to previous therapy. However, when eltrombopag is…”
Get full text
Journal Article -
13
Interaction between capecitabine and brivudin in a patient with breast cancer
Published in Nature reviews. Clinical oncology (01-01-2010)“…This Case Study describes a patient with breast cancer who was treated with capecitabine and experienced a severe adverse event when treated with brivudin for…”
Get full text
Journal Article -
14
Efficacy and Safety of Fostamatinib for Immune Thrombocytopenia in Clinical Practice in Spain: Interim Results of Fostames, Our National Fostamatinib Registry
Published in Blood (02-11-2023)“…Background: Fostamatinib is a splenic tyrosine kinase (SYK) inhibitor that prevents antibody-mediated platelet destruction. This drug has demonstrated to be…”
Get full text
Journal Article -
15
Factor XIII Deficiency As Underlying Cause Of Unexplained Bleeding
Published in Blood (15-11-2013)“…Factor XIII deficiency (FXIII) is an uncommon coagulation disorder. Congenital FXIII deficiency, generally due to mutations in F13A1 gene, presents with early…”
Get full text
Journal Article -
16
Thrombopoietin Analogs In ITP Patients Daily Practice: Treatment Profile, Efficacy and Safety
Published in Blood (15-11-2013)“…Thrombopoietin analogues (TPOa) are an effective alternative of treatment in patients with refractary primary immune thrombocytopenia (ITP) or chronic ITP…”
Get full text
Journal Article -
17
Usefulness of Eltrombopag in Secondary ITP Patients in Clinical Practice
Published in Blood (03-12-2015)“…Background: Eltrombopag is an oral thrombopoietin receptor agonist (TPO-RA) drug approved in primary chronic ITP. Lack of clinical trials in secondary ITP…”
Get full text
Journal Article